A Phase 2 interventional study of Panhematin and Glucose in Acute Porphyrias, sponsored by The University of Texas Medical Branch, Galveston. Completed at 1 site in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-04-11.
Sponsored by The University of Texas Medical Branch, Galveston · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Porphyria, Acute Intermittent with a site in United States — 2 open to participants now, 3 under way, none of them phase 3. Porphyria, Acute Intermittent · United States.
Among the 12 studies in Porphyria, Acute Intermittent with a site in United States, this one is one of 2 that started in 2014, is one of 2 in phase 2, and was the 4th registered.
21 studies on the registry are indexed under Porphyria, Acute Intermittent; 3 are open to participants now.
Browse Porphyria, Acute Intermittent studies →2 of the 12 studies in Porphyria, Acute Intermittent with a site in United States are open now. Recruiting first, the newest first:
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 12+
The American Porphyrias Expert Collaborative · Sites in United States
Ages 1 min+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 3 Porphyria, Acute Intermittent studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 2 take children under 18; none take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 2
First in 2003; this study’s year is marked. 2 started in 2014.
This study's enrollment of 20 is close to the median of 20 across 11 interventional studies indexed under Porphyria, Acute Intermittent.
Median enrollment 28 across the 6 interventional studies, 149 across the 6 observational. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 12 have an industry lead sponsor. The 7 most frequent:
The University of Texas Medical Branch, Galveston is the lead sponsor of 257 studies on the registry; 36 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 26 (81%) have results posted.
The University of Texas Medical Branch, Galveston has 3 studies filed under Porphyria, Acute Intermittent — fewer than ten, so there is no comparison to draw.
1 of the studies in Porphyria, Acute Intermittent with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02935400The University of Texas Medical Branch, GalvestonAcute Porphyria Biomarkers for Disease Activity | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Porphyria, Acute Intermittent with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to provide high quality evidence for the effectiveness and safety of hemin (PanhematinTM , Recordati) for treatment of acute attacks of porphyria. These types of studies have not been done before with either PanhematinTM or the hemin preparation available in Europe (NormosangTM, Orphan Europe).
There are two treatment groups in this study. One group will be treated with PanhematinTM plus glucose, and the other group will be treated with glucose plus an inactive salt solution (called a "placebo"). To avoid prejudice, the treatment given to each participant will be blinded (meaning the participants and most of the hospital staff will not know which treatment the participant will receive) and randomized (meaning participants will have an equal chance of receiving either treatment, like the flip of a coin). A placebo-controlled, randomized study is the standard method used to prove treatments are effective and safe. PanhematinTM and glucose will be given in the same manner as is usual for treating an attack of porphyria. For participants who are chosen to receive the placebo, their treatment will be switched to real PanhematinTM at any time if their symptoms do not improve. This is called "rescue" treatment, and assures that they study is safe and patients who need hemin will receive it. Treatment with hemin will be for 4 days, or longer if needed. Since the study treatment is started as soon as possible after symptoms appear, there will be very little delay in providing hemin to those who need it. Funding Source - Office of Orphan Products Development (FDA OOPD)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Panhematin plus glucose
Biological: Panhematin · Other: Glucose
Placebo (saline) plus glucose
Other: Glucose
Glucose loading
Also known as: Glucose
Glucose is administered to both groups as routine care.
Difference in NRS Pain Score Between Baseline and 12 Hours
The difference in the pre-infusion NRS pain scores and NRS pain score 12 hours from the infusion start time. To define this variable, all blinded study treatment infusion times were compared with the pain score survey times. The pain score closest to but prior to the infusion time was the pre-infusion pain score. Numeric rating scale for pain (0-10; 0=no pain, 10=most severe pain).
Time frame: Baseline and 12 hours
Biochemical Effects of Panhematin In Participants Treated Early For Attacks of Porphyria
Difference in the panhematin and placebo arm for the change in urinary ALA, (PBG), and total porphyrins between baseline and subsequent time points.
Time frame: Day 1 (baseline), Day 2, Day 3 and Day 4
Effects of Clinical Features on Response to Panhematin
Age, sex, exacerbating factors
Time frame: 4 days
Effects of Genetic Features on Response to Panhematin
Types of mutations
Time frame: 4 days
Use of Reconstitution of Panhematin With Albumin
Frequency of side effects or adverse events
Time frame: 4 days
| Milestone | Panhematin | Placebo |
|---|---|---|
| Started | 10 | 10 |
| Completed | 10 | 10 |
| Not completed | 0 | 0 |
The difference in the pre-infusion NRS pain scores and NRS pain score 12 hours from the infusion start time. To define this variable, all blinded study treatment infusion times were compared with the pain score survey times. The pain score closest to but prior to the infusion time was the pre-infusion pain score. Numeric rating scale for pain (0-10; 0=no pain, 10=most severe pain).
| score on a scale | Panhematin | Placebo |
|---|---|---|
| Difference in NRS Pain Score Between Baseline and 12 Hours | -0.2 ± 2.2 | -0.2 ± 1.9 |
Difference in the panhematin and placebo arm for the change in urinary ALA, (PBG), and total porphyrins between baseline and subsequent time points.
| mean difference of mg/g creatinine | Panhematin | Placebo |
|---|---|---|
| ALA Day 1 vs Day 2 | 8.47 ± 8.97 | 2.31 ± 5.5 |
| ALA Day 1 vs Day 3 | 13.27 ± 11.45 | -0.57 ± 6.01 |
| ALA Day 1 vs Day 4 | 14.90 ± 11.85 | 1.99 ± 10.73 |
| PBG Day 1 vs Day 2 | 6.56 ± 11.69 | -2.94 ± 12.85 |
| PBG Day 1 vs Day 3 | 15.56 ± 17.88 | -7.08 ± 10.76 |
| PBG Day 1 vs Day 4 | 20.16 ± 18.63 | -5.83 ± 20.00 |
| Total Porphyrins Day 1 vs Day 2 | 297.60 ± 948.90 | 317.00 ± 682.93 |
| Total Porphyrins Day 1 vs Day 3 | 594.00 ± 1173.48 | 165.00 ± 678.41 |
| Total Porphyrins Day 1 vs Day 4 | 606.11 ± 1238.87 | 331.33 ± 836.59 |
Age, sex, exacerbating factors
Results for this outcome have not been posted.
Types of mutations
Results for this outcome have not been posted.
Frequency of side effects or adverse events
Results for this outcome have not been posted.
Collected over Day 1 (baseline), Day 2, Day 3 and Day 4. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Panhematin | 0/10 (0%) | 0/10 (0%) | 0/10 (0%) |
| Placebo | 0/10 (0%) | 0/10 (0%) | 0/10 (0%) |
| Age, Continuous(years) | Panhematin | Placebo | Total |
|---|---|---|---|
| Mean | 36.6 ± 6.2 | 36.7 ± 11.2 | 36.7 ± 8.8 |
| Sex: Female, Male(Participants) | Panhematin | Placebo | Total |
|---|---|---|---|
| Female | 10 | 10 | 20 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Panhematin | Placebo | Total |
|---|---|---|---|
| Hispanic | 0 | 1 | 1 |
| Non-Hispanic American Indian or Alaskan native | 1 | 0 | 1 |
| Non-Hispanic Asian | 0 | 1 | 1 |
| Non-Hispanic Black or African American | 0 | 2 | 2 |
| Non-Hispanic White | 9 | 6 | 15 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2014 to primary completion in Feb 2022, 93 months.
Results were first posted in Apr 2025, 3 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hemin
Porphyria, Acute Intermittent →
The University of Texas Medical Branch, Galveston →